Innovations
Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST
Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca
According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.
Read
Commented by André Will-Laudien on August 5th, 2026 | 07:20 CEST
Endless NASDAQ Rally – AI Drives Demand for Electric Power and Hydrogen: Nel ASA, dynaCERT, BYD, and ITM Power
While the relentless tech rally on the NASDAQ races from one historic all-time high to the next thanks to the insatiable AI boom, investors are increasingly focusing on the industry's fundamental Achilles' heel: the enormous electricity demand of AI data centers. As artificial intelligence becomes more deeply embedded in business operations, it not only requires vast amounts of electricity but is also automating routine tasks that were once performed by human workers. This rapid adoption is driving an unprecedented need for reliable power generation. The question is no longer whether additional energy will be needed, but where it will come from. Investors looking toward the future are increasingly seeking the most compelling ESG investment opportunities at the intersection of high-tech innovation and energy production. In addition to expanding nuclear energy, many cleantech solutions are being explored. The e-mobility giant BYD recognized this challenge years ago; today, it dominates the roads worldwide with groundbreaking battery technologies. Complementing the electrification trend is the growing hydrogen economy, where Nel ASA and ITM Power continue to play important roles. At the same time, dynaCERT is rapidly advancing toward broader commercial adoption through an ambitious expansion strategy in Asia, leveraging its emissions-reduction technology. Where are the key catalysts for investors?
Read
Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST
"Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future
Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?
Read
Commented by Stefan Feulner on August 3rd, 2026 | 07:05 CEST
Viking Therapeutics, BioNxt Solutions, and Bausch Health: Clinical Success Sparks Fresh Optimism
The pharmaceutical industry is entering a new phase of growth. Billions of dollars are being invested in innovative therapies, advanced drug delivery technologies, and the further development of established medicines. Areas such as metabolic diseases, personalized medicine, and next-generation drug delivery systems are evolving particularly rapidly, with the potential to improve patient outcomes and treatment convenience significantly. At the same time, strong corporate results and rising investments are fueling renewed optimism across the sector. For investors, this brings several companies into focus that could benefit disproportionately from these long-term industry trends.
Read
Commented by Nico Popp on July 23rd, 2026 | 07:50 CEST
Panic in the Multi-Billion-Dollar Market: Novo Nordisk and Halozyme Therapeutics Face Headwinds—BioNxt Solutions Nears a Turning Point
The global pharmaceutical market is worth hundreds of billions of dollars. Yet one of the industry's most surprising realities is that success increasingly depends not only on the active ingredient itself but also on how it is delivered. This does not refer to the cardboard box, but to the dosage form. Whenever patents expire, and blockbuster drugs face competition, innovative biotech companies seize the opportunity. New drug delivery technologies can transform well-known substances into more effective medicines, reduce side effects, and open up entirely new treatment options for patients. While established pharmaceutical giants spend vast sums defending market exclusivity, agile second-tier biotech companies are driving innovation through next-generation drug delivery platforms.
Read
Commented by Fabian Lorenz on July 14th, 2026 | 07:00 CEST
Bayer and Novo Nordisk Celebrate a Comeback! Is BioNxt Solutions Next?
With its GLP-1 therapy in tablet form, Novo Nordisk has returned to success on the stock market. Since April, the Danish pharmaceutical company's stock has risen by nearly 50% to around EUR 43. New research results are now being presented. Bayer has also recently celebrated a comeback on the stock market. Following the landmark glyphosate ruling by the US Supreme Court, hopes are growing that the company will be able to focus more strongly on its core business again in the future. To that end, the Leverkusen-based company has secured EUR 3 billion. BioNxt Solutions could be poised for a comeback. The biotech company's stock has nearly halved in value this year. Yet the news flow is positive and points to rising prices.
Read
Commented by André Will-Laudien on June 24th, 2026 | 08:45 CEST
AI and Chip Sell-Off! Watch Out for SMCI, AMD, and Infineon; First Hydrogen in the Innovation Race
The stock market is currently showing no mercy. After months of gains in AI, high-tech, and chip stocks, the market has now shifted into profit-taking mode—and, at times, even sell-off mode. What analysts have been predicting for quite some time is increasingly coming to pass. The global stock market rally, driven by the NASDAQ, is taking its toll. While the long-term earnings outlook may be solid, short-term price surges of up to 2,000% in just 12 months no longer indicate a healthy market trend. So, while it comes as no surprise, it may be unwelcome for many market participants: a sharper downward move—one that, however, also brings new opportunities in its wake. We examine the fundamental framework of the key players and highlight alternatives for getting off to an innovative start today. The stock market keeps turning—just a little slower at times!
Read
Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST
Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech
On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.
Read
Commented by Nico Popp on June 18th, 2026 | 07:35 CEST
The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma
There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.
Read
Commented by Stefan Feulner on June 15th, 2026 | 07:40 CEST
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination
The biotech sector is currently experiencing tremendous momentum. Therapies for obesity, diabetes, autoimmune diseases, and neurological conditions, in particular, rank among the largest growth markets in the healthcare industry. The booming GLP-1 market for weight loss and metabolic disorders alone is expected to reach a volume of tens of billions of USD in the coming years. At the same time, new classes of active ingredients and innovative delivery technologies are providing fresh momentum. Investors find themselves in an environment where clinical advances and technological innovations can trigger significant increases in value.
Read